Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01033760 | Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) | PHASE3 | COMPLETED | 90 | — | — | Apr 1, 2010 | Dec 1, 2013 | Feb 5, 2014 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| arm 1 | EXPERIMENTAL | darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir |
| arm 2 | ACTIVE_COMPARATOR | darunavir, ritonavir, emtricitabine/tenofovir |
| Name | Type | Description |
|---|---|---|
| raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine | DRUG | raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD. |
| darunavir; ritonavir; emtricitabine/tenofovir | DRUG | darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD. |
Inclusion Criteria: * Patients with acute or primary HIV-1 infection * Acute infection: negative or slightly positive Elisa, with negative or incomplete western-blot (0 or 1 antibody) and positive HIV-RNA and/or positive Ag p24. * Primary infection: positive Elisa with incomplete Western-blot (≥ 2 ...